Formulation Development
GRIN Therapeutics Receives Priority Medicines Designation From EMA for Radiprodil in the Treatment of GRIN-Related Neurodevelopmental Disorder
GRIN Therapeutics, Inc. recently announced that the European Medicines Agency (EMA) has granted Priority Medicine (PRIME) designation to radiprodil, the company’s investigational, potent negative allosteric…
Moleculin Doses First Patient in Pivotal Adaptive Phase 3 MIRACLE Trial
Moleculin Biotech, Inc. recently announced the first patient has been dosed in its Phase 3 pivotal trial evaluating Annamycin in combination with Cytarabine (also known…
DDL Launches New GMP Lab for Drug Delivery Testing
DDL, a leading provider of package, product, and material testing services, recently announce the opening of a new Good Manufacturing Practice (GMP) laboratory dedicated to…
Gyre Therapeutics Announces NMPA Approval for Clinical Trial Evaluating Pirfenidone Capsules in Oncology-Related Pulmonary Complications
Gyre Therapeutics recently announced that the National Medical Products Administration (NMPA) of the People’s Republic of China (PRC) has approved its clinical trial application for…
Trethera Treats a Late Stage, Heavily Pretreated Amyotrophic Lateral Sclerosis Patient With TRE 515
Trethera Corporation recently announced clinical results from treating a patient with ALS (amyotrophic lateral sclerosis, also known as Lou Gehrig’s disease) with TRE-515 under the…
Apollomics & LaunXP Announce Development & Commercialization Agreement for Vebreltinib
Apollomics Inc. and LaunXP International Co., Ltd. recently announced the parties have entered into an agreement for the development and commercialization in Asia (excluding mainland…
NeOnc Technologies Receives Rare Pediatric Disease Designation for NEO100 in Treatment of Pediatric-Type Diffuse High-Grade Gliomas
NeOnc Technologies Holdings, Inc. recently announced the US FDA has granted Rare Pediatric Disease Designation (RPDD) to perillyl alcohol (NEO100) for the treatment of pediatric-type…
CERo Therapeutics Holdings Receives FDA Clearance of Second Investigational NDA to Initiate Phase 1 Clinical Trial of Lead Compound CER-1236 in Solid Tumors
CERo Therapeutics Holdings, Inc. recently announced it has received clearance by the US FDA for a second Investigational New Drug (IND) application for lead compound…
Conduit Pharmaceuticals Receives US Patent Approval for Its Lead Asset Targeting Autoimmune Diseases
Conduit Pharmaceuticals Inc. recently announced that the United States Patent and Trademark Office (USPTO) has granted the composition of matter patent for its lead asset,…
LIXTE Launches New Study to Determine if Certain Pre-Cancerous Cells Found in an Aging Population Can Be Eliminated by LB-100
LIXTE Biotechnology Holdings, Inc recently announced it will conduct a new pre-clinical study in collaboration with Netherlands Cancer Institute (NKI) to test whether “initiated” cells that…
Lexicon Pharmaceuticals Announces Exclusive License Agreement With Novo Nordisk
Lexicon Pharmaceuticals, Inc. recently announced it has entered into an exclusive license agreement with Novo Nordisk A/S for LX9851, a first-in-class, oral non-incretin development candidate…
Silexion Therapeutics Unveils Innovative Expanded Development Plan for SIL204 Based on Recent Groundbreaking Preclinical Data
Silexion Therapeutics Corp. recently announced an expanded development plan for its next-generation siRNA candidate, SIL204. This strategy integrates systemic administration to target metastatic progression with…
Ocean Biomedical Announces Grant on Patent Right for Bispecific Antibodies Targeting CHI3L1 & PD1 for Enhanced Tumor Cell Cytotoxicity
Ocean Biomedical, Inc. recently announced the China National Intellectual Property Administration (CNIPA) has granted a notice of grant on patent right for its bispecific antibodies…
Regulus Therapeutics Announces Successful Completion of its Phase 1b MAD Clinical Trial for Autosomal Dominant Polycystic Kidney Disease Treatment
Regulus Therapeutics Inc. recently announced positive topline results from all patients in the fourth cohort in its Phase 1b MAD study of farabursen for the treatment…
WHITEPAPER - 3D SCREEN Printing: Enabling a New Generation of Complex Formulations
By overcoming key challenges 3D screen printing is unlocking new possibilities in drug development and manufacturing.
Gyre Therapeutics Announces Publication of Protocol for Phase 3 Trial Evaluating F351 for CHB-Associated Liver Fibrosis
Gyre Therapeutics recently announced the publication of the manuscript titled Hydronidone for the Treatment of Liver Fibrosis Associated with Chronic Hepatitis B: Protocol for a…
Galatea Bio Secures $25M to Develop Global Biobank & Enable Precision Health at Scale for All
Galatea Bio has secured $25 million in funding to drive discoveries in next-generation genetic analysis, biomarker discovery, and multi-omics disease modeling. Committed to enabling precision health…
NeOnc Technologies Expands Global Clinical Trial Network With CBCC Global Research to Accelerate Study of Brain Cancer Treatments
NeOnc Technologies Holdings, Inc. recently announced a strategic partnership with CBCC Global Research (CBCC), a premier full-service clinical research organization (CRO). This collaboration will expand NeOnc’s…
CERo Therapeutics Holdings Poised to Initiate Enrollment of Phase 1 Trial of CER-1236 in AML Following Positive FDA Review of Manufacturing
CERo Therapeutics Holdings, Inc. recently announced that the company has received positive review from the US FDA on an amendment to its IND around Chemistry,…
Polyrizon Structures Clinical Strategy for its Allergy Blocker Ahead of FDA Pre-Submission Meeting
Polyrizon Ltd. recenytly announced the structuring of its clinical strategy for PL-14, the company’s proprietary intranasal allergy blocker for seasonal allergic rhinitis. The clinical strategy…
